Effect of rituximab on peripheral blood stem cell mobilization and engraftment kinetics in non-Hodgkin's lymphoma patients. (Q44470469)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12838277 AND SRC:MED&resulttype=core&format=json

5 November 2019

title

Effect of rituximab on peripheral blood stem cell mobilization and engraftment kinetics in non-Hodgkin's lymphoma patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12838277 AND SRC:MED&resulttype=core&format=json

5 November 2019

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12838277 AND SRC:MED&resulttype=core&format=json

5 November 2019

author name string

Hahn T

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12838277 AND SRC:MED&resulttype=core&format=json

5 November 2019

Shafi F

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12838277 AND SRC:MED&resulttype=core&format=json

5 November 2019

Qureshi A

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12838277 AND SRC:MED&resulttype=core&format=json

5 November 2019

Alam AR

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12838277 AND SRC:MED&resulttype=core&format=json

5 November 2019

Czuczman MS

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12838277 AND SRC:MED&resulttype=core&format=json

5 November 2019

Bernstein ZP

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12838277 AND SRC:MED&resulttype=core&format=json

5 November 2019

Chanan-Khan AA

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12838277 AND SRC:MED&resulttype=core&format=json

5 November 2019

Becker JL

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12838277 AND SRC:MED&resulttype=core&format=json

5 November 2019

McCarthy PL

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12838277 AND SRC:MED&resulttype=core&format=json

5 November 2019

language of work or name

English

0 references

publication date

1 July 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12838277 AND SRC:MED&resulttype=core&format=json

Bone Marrow Transplantation

5 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12838277 AND SRC:MED&resulttype=core&format=json

5 November 2019

volume

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12838277 AND SRC:MED&resulttype=core&format=json

5 November 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12838277 AND SRC:MED&resulttype=core&format=json

5 November 2019

page(s)

139-143

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12838277 AND SRC:MED&resulttype=core&format=json

High-dose therapy in lymphomas: a review of the current status of allogeneic and autologous stem cell transplantation in Hodgkin's disease and non-Hodgkin's lymphoma

5 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1038/SJ.BMT.1704106

The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of diffuse large cell B-cell non-Hodgkin's lymphoma: an evidence-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.BMT.1704106

Rituximab: ongoing and future clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.BMT.1704106

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.BMT.1704106

A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.BMT.1704106

Monoclonal antibodies and autologous stem cell transplantation for lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.BMT.1704106

Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.BMT.1704106

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.BMT.1704106

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.BMT.1704106

Control of the complement system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.BMT.1704106

Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.BMT.1704106

Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.BMT.1704106

7 January 2021

Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038/SJ.BMT.1704106

7 January 2021

Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038/SJ.BMT.1704106

7 January 2021

Fludarabine-containing regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukaemia patients

1 reference

https://api.crossref.org/works/10.1038/SJ.BMT.1704106

7 January 2021

Fludarabine containing-regimens may adversely affect peripheral blood stem cell collection in low-grade non Hodgkin lymphoma patients

1 reference

https://api.crossref.org/works/10.1038/SJ.BMT.1704106

7 January 2021

Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1038/SJ.BMT.1704106

7 January 2021

Factors that influence collection and engraftment of autologous peripheral-blood stem cells

1 reference

https://api.crossref.org/works/10.1038/SJ.BMT.1704106

7 January 2021

European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma

1 reference

https://api.crossref.org/works/10.1038/SJ.BMT.1704106

7 January 2021

Complement activation plays a key role in the side-effects of rituximab treatment

1 reference

https://api.crossref.org/works/10.1038/SJ.BMT.1704106

7 January 2021